Combination therapy involving diaryl macrocyclic compounds

The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.

Saved in:
Bibliographic Details
Main Authors Murray, Brion W, Cui, Jingrong J, Deng, Wei, Rodon, Laura, Zhai, Dayong, Lee, Nathan V
Format Patent
LanguageEnglish
Published 06.06.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
Bibliography:Application Number: US202017104739